USPTO Patent Application: RNA Complexes for Cancer Metastasis Treatment

ChangeBridge: Patent Apps - Pharma (A61K)

Published September 28th, 2023

Detected March 26th, 2026

Summary

The USPTO has published a new patent application detailing RNA complexes and nanostructures for cancer metastasis treatment. The application describes a one-step CMC production method for RNA therapeutic complexes containing nucleoside analogues, which self-assemble during RNA synthesis.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083770A1) filed on September 28, 2023, concerning novel RNA complexes and nanostructures for treating cancer metastasis. The invention focuses on a simplified, one-step CMC production process for RNA therapeutic complexes that incorporate nucleoside analogues, allowing for self-assembly during RNA synthesis without additional conjugation steps.

As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in pharmaceutical and biotechnology research. Companies in the pharmaceutical and medical device sectors involved in oncology treatments should be aware of this technological advancement for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

RNA COMPLEXES AND NANOSTRUCTURES FOR TREATMENT OF CANCER METASTASIS

Application US20260083770A1 Kind: A1 Mar 26, 2026

Inventors

Peixuan GUO, Xin LI, Daniel BINZEL, Kai JIN

Abstract

Disclosed herein are compositions and methods for one step CMC production of RNA therapeutic complexes (nanostructures) that contain nucleoside analogues. In some embodiments, the nucleoside analogues are incorporated into RNA oligonucleotides that self-assemble into an RNA complex during RNA synthesis in a one-step production. Therefore, no additional conjugation or synthesis processes are required.